Efficacy and safety of once-daily roflumilast cream 0.3% in patients with knee/elbow involvement: Pooled results from phase 3 trials (DERMIS-1 and DERMIS-2)

被引：0
|
作者：
Ferris, Laura K. [1 ]
Draelos, Zoe D. [2 ]
Hebert, Adelaide A. [3 ]
Lynde, Charles W. [4 ]
Pariser, David M. [5 ,6 ]
Papp, Kim A. [7 ,8 ]
Yamauchi, Paul S. [9 ,10 ]
Feng, Amy [11 ]
Higham, Robert C. [11 ]
Burnett, Patrick [11 ]
Berk, David R. [11 ]
机构：
[1] Univ Pittsburgh, Dept Dermatol, Pittsburgh, PA 15260 USA
[2] Dermatol Consulting Serv, High Point, NC USA
[3] UT Hlth McGovern Med Sch, Houston, TX USA
[4] Lynderm Res Inc, Markham, ON, Canada
[5] Eastern Virginia Med Sch, Norfolk, VA USA
[6] Virginia Clin Res Inc, Norfolk, VA USA
[7] Prob Med Res, Waterloo, ON, Canada
[8] K Papp Clin Res, Waterloo, ON, Canada
[9] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[10] Dermatol Inst & Skin Care Ctr Inc, Santa Monica, CA USA
[11] Arcutis Biotherapeut Inc, Westlake Village, VA USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2022年 / 87卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
33468
引用
收藏
页码：AB162 / AB162
页数：1
相关论文
共 50 条
  • [31] Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 analogue, in Latino/Hispanic patients with type 2 diabetes: post hoc analysis of data from four phase III trials
    Davidson, J. A.
    Orsted, D. D.
    Campos, C.
    DIABETES OBESITY & METABOLISM, 2016, 18 (07): : 725 - 728
  • [32] Efficacy and Safety of Once-Daily Linaclotide Administered Orally for 26 Weeks in Patients With IBS-C: Results From a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial
    Chey, William D.
    Lembo, Anthony
    MacDougall, James E.
    Lavins, Bernard J.
    Schneier, Harvey
    Johnston, Jeffrey M.
    GASTROENTEROLOGY, 2011, 140 (05) : S135 - S135
  • [33] Efficacy and Safety of Once Daily Linaclotide Administered Orally for 12-Weeks in Patients With Chronic Constipation: Results From 2 Randomized, Double-Blind, Placebo-Controlled Phase 3 Trials
    Lembo, Anthony
    Schneier, Harvey
    Lavins, Bernard J.
    Shiff, Steven J.
    MacDougall, James E.
    Jia, Xinwei D.
    Kurtz, Caroline B.
    Currie, Mark G.
    Johnston, Jeffrey M.
    GASTROENTEROLOGY, 2010, 138 (05) : S53 - S54
  • [34] EFFICACY AND SAFETY OF AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS: POOLED RESULTS FROM THE PHASE 1 EXPLORER AND INTERIM PHASE 2 PATHFINDER STUDIES
    Vannucchi, A. M.
    Radia, D.
    DeAngelo, D.
    Deininger, M.
    Reiter, A.
    Lin, H. M.
    Dimitrijevic, S.
    Gotlib, J.
    HAEMATOLOGICA, 2022, 107 : 25 - 26
  • [35] Comparison of the Efficacy and Tolerability Profile of Liraglutide, a Once-Daily Human GLP-1 Analog, in Patients With Type 2 Diabetes ≥65 and <65 Years of Age: A Pooled Analysis from Phase III Studies
    Bode, Bruce W.
    Brett, Jason
    Falahati, Ali
    Pratley, Richard E.
    AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY, 2011, 9 (06): : 423 - 433
  • [36] Tapinarof cream 1% once daily is efficacious for the treatment of atopic dermatitis in patients with skin of color down to 2 years of age in two pivotal phase 3 trials
    Alexis, Andrew F.
    Kircik, Leon
    Chovatiya, Raj
    Rice, Zakiya P.
    Bhutani, Tina
    Brown, Philip M.
    Piscitelli, Stephen C.
    Rubenstein, David S.
    Tallman, Anna M.
    Armstrong, April W.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : 45 - 46
  • [37] Efficacy and safety of roflumilast cream 0.15% in adults and children aged=6 years with mild to moderate atopic dermatitis in two phase 3 trials (INTEGUMENT-1 and INTEGUMENT-2)
    Simpson, Eric
    Eichenfield, Lawrence
    Gooderham, Melinda
    Gonzalez, Mercedes E.
    Hebert, Adelaide
    Papp, Kim
    Prajapati, Vimal
    Krupa, David
    Burnett, Patrick
    Berk, David
    Higham, Robert
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [38] Efficacy and safety of once-weekly oral trelagliptin switched from once-daily dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: An open-label, phase 3 exploratory study
    Inagaki, Nobuya
    Sano, Hiroki
    Seki, Yoshifumi
    Kuroda, Shingo
    Kaku, Kohei
    JOURNAL OF DIABETES INVESTIGATION, 2018, 9 (02) : 354 - 359
  • [39] EFFICACY AND TOLERABILITY OF ONCE-DAILY MIRABEGRON, A POTENT AND SELECTIVE B3-ADRENOCEPTOR AGONIST, IN PATIENTS WITH OVERACTIVE BLADDER - RESULTS FROM A NORTH AMERICAN PHASE III TRIAL
    Nitti, V
    Herschorn, S.
    Lee, M.
    Martin, N.
    NEUROUROLOGY AND URODYNAMICS, 2011, 30 (06) : 927 - 929
  • [40] Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials
    Silverberg, Jonathan I.
    Eichenfield, Lawrence F.
    Hebert, Adelaide A.
    Simpson, Eric L.
    Gold, Linda Stein
    Bissonnette, Robert
    Papp, Kim A.
    Browning, John
    Kwong, Pearl
    Korman, Neil J.
    Brown, Philip M.
    Rubenstein, David S.
    Piscitelli, Stephen C.
    Somerville, Matthew C.
    Tallman, Anna M.
    Kircik, Leon
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 91 (03) : 457 - 465
12345